Strategies for combining immunotherapy with radiation for anticancer therapy
Posted: Thu Jan 04, 2018 7:10 pm
Strategies for combining immunotherapy with radiation for anticancer therapy
Immunotherapy. Author manuscript; available in PMC 2016 Apr 8.
Published in final edited form as:
Immunotherapy. 2015; 7(9): 967–980.
Published online 2015 Aug 27. doi: 10.2217/imt.15.65
Abstract
Radiation therapy controls local disease but also prompts the release of tumor-associated antigens and stress-related danger signals that primes T cells to promote tumor regression at unirradiated sites known as the abscopal effect. This may be enhanced by blocking inhibitory immune signals that modulate immune activity through a variety of mechanisms. Indeed, abscopal responses have occurred in patients with lung cancer or melanoma when given anti-CTLA4 antibody and radiation. Other approaches involve expanding and reinfusing T or NK cells or engineered T cells to express receptors that target specific tumor peptides. These approaches may be useful for immunocompromised patients receiving radiation. Preclinical and clinical studies are testing both immune checkpoint–based strategies and adoptive immunotherapies with radiation.
https://www.ncbi.nlm.nih.gov/pmc/articl ... po=40.4348
Immunotherapy. Author manuscript; available in PMC 2016 Apr 8.
Published in final edited form as:
Immunotherapy. 2015; 7(9): 967–980.
Published online 2015 Aug 27. doi: 10.2217/imt.15.65
Abstract
Radiation therapy controls local disease but also prompts the release of tumor-associated antigens and stress-related danger signals that primes T cells to promote tumor regression at unirradiated sites known as the abscopal effect. This may be enhanced by blocking inhibitory immune signals that modulate immune activity through a variety of mechanisms. Indeed, abscopal responses have occurred in patients with lung cancer or melanoma when given anti-CTLA4 antibody and radiation. Other approaches involve expanding and reinfusing T or NK cells or engineered T cells to express receptors that target specific tumor peptides. These approaches may be useful for immunocompromised patients receiving radiation. Preclinical and clinical studies are testing both immune checkpoint–based strategies and adoptive immunotherapies with radiation.
https://www.ncbi.nlm.nih.gov/pmc/articl ... po=40.4348